Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 2
1965 1
1968 1
1970 1
1971 2
1972 6
1973 18
1974 15
1975 30
1976 35
1977 29
1978 16
1979 18
1980 20
1981 24
1982 14
1983 22
1984 15
1985 11
1986 15
1987 17
1988 13
1989 9
1990 19
1991 22
1992 5
1993 13
1994 6
1995 12
1996 6
1997 6
1998 12
1999 7
2000 18
2001 8
2002 14
2003 32
2004 40
2005 44
2006 51
2007 71
2008 52
2009 64
2010 92
2011 113
2012 145
2013 135
2014 144
2015 185
2016 225
2017 281
2018 382
2019 574
2020 845
2021 204
Text availability
Article attribute
Article type
Publication date

Search Results

3,718 results
Results by year
Filters applied: . Clear all
Page 1
Cannabidiol Adverse Effects and Toxicity.
Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP. Huestis MA, et al. Curr Neuropharmacol. 2019;17(10):974-989. doi: 10.2174/1570159X17666190603171901. Curr Neuropharmacol. 2019. PMID: 31161980 Free PMC article. Review.
BACKGROUND: Currently, there is a great interest in the potential medical use of cannabidiol (CBD), a non-intoxicating cannabinoid. Productive pharmacological research on CBD occurred in the 1970s and intensified recently with many discoveries about the endocannabinoid sys …
BACKGROUND: Currently, there is a great interest in the potential medical use of cannabidiol (CBD), a non-intoxicating cannabinoid. P …
Cannabidiol, neuroprotection and neuropsychiatric disorders.
Campos AC, Fogaça MV, Sonego AB, Guimarães FS. Campos AC, et al. Pharmacol Res. 2016 Oct;112:119-127. doi: 10.1016/j.phrs.2016.01.033. Epub 2016 Feb 1. Pharmacol Res. 2016. PMID: 26845349 Review.
Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from Cannabis sativa. ...
Cannabidiol (CBD) is a non-psychotomimetic phytocannabinoid derived from Cannabis sativa. ...
The potential of cannabidiol in the COVID-19 pandemic.
Esposito G, Pesce M, Seguella L, Sanseverino W, Lu J, Corpetti C, Sarnelli G. Esposito G, et al. Br J Pharmacol. 2020 Nov;177(21):4967-4970. doi: 10.1111/bph.15157. Epub 2020 Jul 16. Br J Pharmacol. 2020. PMID: 32519753 Free PMC article.
Identifying drugs effective in the new coronavirus disease 2019 (COVID-19) is crucial, pending a vaccine against SARS-CoV2. We suggest the hypothesis that cannabidiol (CBD), a non-psychotropic phytocannabinoid, has the potential to limit the severity and progression of the …
Identifying drugs effective in the new coronavirus disease 2019 (COVID-19) is crucial, pending a vaccine against SARS-CoV2. We suggest the h …
Cannabidiol as a Potential Treatment for Anxiety Disorders.
Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Blessing EM, et al. Neurotherapeutics. 2015 Oct;12(4):825-36. doi: 10.1007/s13311-015-0387-1. Neurotherapeutics. 2015. PMID: 26341731 Free PMC article. Review.
Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasing interest as a treatment for a range of neuropsychiatric disorders. ...
Cannabidiol (CBD), a Cannabis sativa constituent, is a pharmacologically broad-spectrum drug that in recent years has drawn increasin
Trial of Cannabidiol for Drug-Resistant Seizures in the Dravet Syndrome.
Devinsky O, Cross JH, Laux L, Marsh E, Miller I, Nabbout R, Scheffer IE, Thiele EA, Wright S; Cannabidiol in Dravet Syndrome Study Group. Devinsky O, et al. N Engl J Med. 2017 May 25;376(21):2011-2020. doi: 10.1056/NEJMoa1611618. N Engl J Med. 2017. PMID: 28538134 Free article. Clinical Trial.
The percentage of patients who became seizure-free was 5% with cannabidiol and 0% with placebo (P=0.08). Adverse events that occurred more frequently in the cannabidiol group than in the placebo group included diarrhea, vomiting, fatigue, pyrexia, somnolence, and ab …
The percentage of patients who became seizure-free was 5% with cannabidiol and 0% with placebo (P=0.08). Adverse events that occurred …
Epilepsy and cannabidiol: a guide to treatment.
Arzimanoglou A, Brandl U, Cross JH, Gil-Nagel A, Lagae L, Landmark CJ, Specchio N, Nabbout R, Thiele EA, Gubbay O, The Cannabinoids International Experts Panel; Collaborators. Arzimanoglou A, et al. Epileptic Disord. 2020 Feb 1;22(1):1-14. doi: 10.1684/epd.2020.1141. Epileptic Disord. 2020. PMID: 32096470 Free article. Review.
The growing interest in cannabidiol (CBD), specifically a pure form of CBD, as a treatment for epilepsy, among other conditions, is reflected in recent changes in legislation in some countries. ...
The growing interest in cannabidiol (CBD), specifically a pure form of CBD, as a treatment for epilepsy, among other conditions, is r …
Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy.
Samanta D. Samanta D. Pediatr Neurol. 2019 Jul;96:24-29. doi: 10.1016/j.pediatrneurol.2019.03.014. Epub 2019 Mar 22. Pediatr Neurol. 2019. PMID: 31053391 Review.
The exact antiepileptic mechanism of cannabidiol is currently not known, but it modulates a number of endogenous systems and may have a novel anticonvulsant effect. ...Additionally, the FDA-approved pharmaceutical-grade cannabidiol oil is expensive, and insurance co …
The exact antiepileptic mechanism of cannabidiol is currently not known, but it modulates a number of endogenous systems and may have …
Cannabidiol: State of the art and new challenges for therapeutic applications.
Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M. Pisanti S, et al. Pharmacol Ther. 2017 Jul;175:133-150. doi: 10.1016/j.pharmthera.2017.02.041. Epub 2017 Feb 22. Pharmacol Ther. 2017. PMID: 28232276 Review.
Over the past years, several lines of evidence support a therapeutic potential of Cannabis derivatives and in particular phytocannabinoids. delta(9)-THC and cannabidiol (CBD) are the most abundant phytocannabinoids in Cannabis plants and therapeutic application for both co …
Over the past years, several lines of evidence support a therapeutic potential of Cannabis derivatives and in particular phytocannabinoids. …
Cannabidiol in patients with treatment-resistant epilepsy: an open-label interventional trial.
Devinsky O, Marsh E, Friedman D, Thiele E, Laux L, Sullivan J, Miller I, Flamini R, Wilfong A, Filloux F, Wong M, Tilton N, Bruno P, Bluvstein J, Hedlund J, Kamens R, Maclean J, Nangia S, Singhal NS, Wilson CA, Patel A, Cilio MR. Devinsky O, et al. Lancet Neurol. 2016 Mar;15(3):270-8. doi: 10.1016/S1474-4422(15)00379-8. Epub 2015 Dec 24. Lancet Neurol. 2016. PMID: 26724101 Clinical Trial.
The primary objective was to establish the safety and tolerability of cannabidiol and the primary efficacy endpoint was median percentage change in the mean monthly frequency of motor seizures at 12 weeks. ...The median reduction in monthly motor seizures was 36.5% (IQR 0- …
The primary objective was to establish the safety and tolerability of cannabidiol and the primary efficacy endpoint was median percen …
Cannabidiol in Anxiety and Sleep: A Large Case Series.
Shannon S, Lewis N, Lee H, Hughes S. Shannon S, et al. Perm J. 2019;23:18-041. doi: 10.7812/TPP/18-041. Perm J. 2019. PMID: 30624194 Free PMC article.
CONTEXT: Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. ...In this chart review, CBD was well tolerated in all but 3 patients. CONCLUSION: Cannabidiol may hold benefit for anxiety-related disorders. Controlled clinical studies are needed.. …
CONTEXT: Cannabidiol (CBD) is one of many cannabinoid compounds found in cannabis. ...In this chart review, CBD was well tolerated in …
3,718 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page